Whitney S. Graybill

Whitney S. Graybill

Gynecologic Oncology | Obstetrics and Gynecology

1280 Hospital Drive
Mount Pleasant, SC 29464

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 35 publications

Updated patient-reported outcomes and the effect of disease progression on health-related quality of life in the PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer.

Updated patient-reported outcomes and the effect of disease progression on health-related quality of life in the PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer.

Journal: Gynecologic oncology

Published: April 12, 2026

Correlates of Serum Concentrations of Biomarkers Relevant to Ovarian Cancer Screening.

Correlates of Serum Concentrations of Biomarkers Relevant to Ovarian Cancer Screening.

Journal: The journal of applied laboratory medicine

Published: July 08, 2025

Use of individualized starting dose and niraparib hematologic adverse event management costs in ovarian cancer.

Use of individualized starting dose and niraparib hematologic adverse event management costs in ovarian cancer.

Journal: Journal of comparative effectiveness research

Published: December 06, 2024

Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trial.

Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trial.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: July 29, 2024

Predictors of long-term progression-free survival in patients with ovarian cancer treated with niraparib in the PRIMA/ENGOT-OV26/GOG-3012 study.

Predictors of long-term progression-free survival in patients with ovarian cancer treated with niraparib in the PRIMA/ENGOT-OV26/GOG-3012 study.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Published: July 01, 2024

Patterns of initial ovarian cancer recurrence on niraparib maintenance monotherapy in patients with no baseline evidence of disease after first-line chemotherapy: An ad hoc subgroup analysis of PRIMA/ENGOT-OV26/GOG-3012.

Patterns of initial ovarian cancer recurrence on niraparib maintenance monotherapy in patients with no baseline evidence of disease after first-line chemotherapy: An ad hoc subgroup analysis of PRIMA/ENGOT-OV26/GOG-3012.

Journal: Gynecologic oncology

Published: May 08, 2024

Potential Synergistic Effect between Niraparib and Statins in Ovarian Cancer Clinical Trials.

Potential Synergistic Effect between Niraparib and Statins in Ovarian Cancer Clinical Trials.

Journal: Cancer research communications

Published: March 27, 2024

Progression-free survival and safety at 3.5 years of follow-up: results from the randomized phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer - a plain language summary.

Progression-free survival and safety at 3.5 years of follow-up: results from the randomized phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer - a plain language summary.

Journal: Future oncology (London, England)

Published: March 19, 2024

Niraparib Population Pharmacokinetics and Exposure-Response Relationships in Patients With Newly Diagnosed Advanced Ovarian Cancer.

Niraparib Population Pharmacokinetics and Exposure-Response Relationships in Patients With Newly Diagnosed Advanced Ovarian Cancer.

Journal: Clinical therapeutics

Published: January 30, 2024

Efficacy and safety of niraparib in patients aged 65 years and older with advanced ovarian cancer: Results from the PRIMA/ENGOT-OV26/GOG-3012 trial.

Efficacy and safety of niraparib in patients aged 65 years and older with advanced ovarian cancer: Results from the PRIMA/ENGOT-OV26/GOG-3012 trial.

Journal: Gynecologic oncology

Published: December 06, 2023

Optimizing disease progression assessment using blinded central independent review and comparing it with investigator assessment in the PRIMA/ENGOT-ov26/GOG-3012 trial: challenges and solutions.

Optimizing disease progression assessment using blinded central independent review and comparing it with investigator assessment in the PRIMA/ENGOT-ov26/GOG-3012 trial: challenges and solutions.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Published: November 06, 2023

A phase III, multicenter, randomized study of olvimulogene nanivacirepvec followed by platinum-doublet chemotherapy and bevacizumab compared with platinum-doublet chemotherapy and bevacizumab in women with platinum-resistant/refractory ovarian cancer.

A phase III, multicenter, randomized study of olvimulogene nanivacirepvec followed by platinum-doublet chemotherapy and bevacizumab compared with platinum-doublet chemotherapy and bevacizumab in women with platinum-resistant/refractory ovarian cancer.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Published: September 04, 2023

Showing 1-12 of 35

Last Updated: 09/26/2026